Peripherally applied synthetic tetrapeptides HAEE and RADD slow down the development of cerebral β-amyloidosis in AβPP/PS1 transgenic mice

Journal of Alzheimer's Disease

Volumn 46, Issue 4, 2015, Pages 849-853

  Tsvetkov, Philipp O ^a,b   Cheglakov, Ivan B ^c   Ovsepyan, Armen A ^c   Mediannikov, Oleg Y ^d   Morozov, Alexander O ^d   Telegin, Georgy B ^c   Kozin, Sergey A ^d  

^a University of the Mediterranean Aix Marseille II   (France)

^b INSTITUTE OF GENERAL PATHOLOGY AND PATHOPHYSIOLOGY   (Russian Federation)

^c SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

^d Kimonella Ventures Ltd   (Cyprus)

Author keywords

Alzheimer's disease; amyloid ; mouse models; protein aggregation in vivo

Indexed keywords

AMYLOID PRECURSOR PROTEIN; BRAIN PROTEIN; CONGO RED; HAEE TETRAPEPTIDE; PROTEIN PS1; RADD TETRAPEPTIDE; SYNTHETIC PEPTIDE; TETRAPEPTIDE; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; NEUROLEPTIC AGENT; OLIGOPEPTIDE; PRESENILIN 1;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN TUMOR; CEREBRAL BETA AMYLOIDOSIS; CONTROLLED STUDY; DIMERIZATION; DISEASE COURSE; FEMALE; FLUORESCENCE MICROSCOPY; HIPPOCAMPUS; INFANT; MALE; METAL BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; ANIMAL; BRAIN; C57BL MOUSE; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; GENETICS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MUTATION; PATHOLOGY; PLAQUE, AMYLOID; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; DISEASE MODELS, ANIMAL; HUMANS; INJECTIONS, INTRAVENOUS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; OLIGOPEPTIDES; PLAQUE, AMYLOID; PRESENILIN-1;

EID: 84937045436     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-150031     Document Type: Article

References (29)

1. Gandy S, Simon AJ, Steele JW, Lublin AL, Lah JJ, Walker LC, Levey AI, Krafft GA, Levy E, Checler F, Glabe C, Bilker WB, Abel T, Schmeidler J, Ehrlich ME (2010) Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-beta oligomers. Ann Neurol 68, 220-230.
2. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297, 353-356.
3. 42 levels in yeast. J Alzheimers Dis 32, 949-967.
4. Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M (2010) Alzheimer's disease: Clinical trials and drug development. Lancet Neurol 9, 702-716.
5. Karran E, Mercken M, De Strooper B (2011) The amyloid cascade hypothesis for Alzheimer's disease: An appraisal for the development of therapeutics. Nat Rev Drug Discov 10, 698-712.
6. Bush AI (2013) The metal theory of Alzheimer's disease. J Alzheimers Dis 33, S277-S281.
7. Faller P, Hureau C (2009) Bioinorganic chemistry of copper and zinc ions coordinated to amyloid-β peptide. Dalton Trans, 1080-1094.
8. Zirah S, Kozin SA, Mazur AK, Blond A, Cheminant M, Segalas-Milazzo I, Debey P, Rebuffat S (2006) Structural changes of region 1-16 of the Alzheimer disease amyloid β-peptide upon zinc binding and in vitro aging. J Biol Chem 281, 2151-2161.
9. 2+ binding site of amyloid-β. Biophys J 99, L84-L86.
10. II-Ab11-28 aggregates. Inorg Chem 51, 7897-7902.
11. Kozin SA, Kulikova AA, Istrate AN, Tsvetkov PO, Zhokhov SS, Mezentsev YV, Kechko OI, Ivanov AS, Polshakov VI, Makarov AA (2015) The English (H6R) familial Alzheimer's disease mutation facilitates zinc-induced dimerization of the amyloid-β metal-binding domain. Metallomics 7, 422-425.
12. Kozin SA, Mezentsev YV, Kulikova AA, Indeykina MI, Golovin AV, Ivanov AS, Tsvetkov PO, Makarov AA (2011) Zinc-induced dimerization of the amyloid-β metal-binding domain 1-16 is mediated by residues 11-14. Mol BioSyst 7, 1053-1055.
13. Kulikova AA, Tsvetkov PO, Indeykina MI, Popov IA, Zhokhov SS, Golovin AV, Polshakov VI, Kozin SA, Nudler E, Makarov AA (2014) Phosphorylation of Ser8 promotes zinc-induced dimerization of the amyloid-β metal-binding domain. Mol BioSyst 10, 2590-2596.
14. Miller Y, Ma B, Nussinov R (2010) Zinc ions promote Alzheimer Aβ aggregation via population shift of polymorphic states. Proc Natl Acad Sci USA107, 9490-9495.
15. Mediannikov O, Morozov A. Peptide compound useful for inhibiting amyloid plaque formation. France Patent 2,966,827, filed October 10, 2010, and issued August 22, 2014.
16. Yardeni T, Eckhaus M, Morris HD, Huizing M, Hoogstraten-Miller S (2011) Retro-orbital injections in mice. Lab Anim (NY) 40, 155-160.
17. Peters OM, Connor-Robson N, Sokolov VB, Aksinenko AY, Kukharsky MS, Bachurin SO, Ninkina N, Buchman VL (2013) Chronic administration of dimebon ameliorates pathology in TauP301S transgenic mice. J Alzheimers Dis 33, 1041-1049.
18. Peters OM, Shelkovnikova T, Tarasova T, Springe S, Kukharsky MS, Smith GA, Brooks S, Kozin SA, Kotelevtsev Y, Bachurin SO, Ninkina N, Buchman VL (2013) Chronic administration of dimebon does not ameliorate amyloid-β pathology in 5xFAD transgenic mice. J Alzheimers Dis 36, 589-596.
19. Surgucheva I, Ninkina N, Buchman V, Grasing K, Surguchov A (2005) Protein aggregation in retinal cells and approaches to cell protection. Cell Mol Neurobiol 25, 1051-1066.
20. Borchelt DR, Ratovitski T, van Lare J, Lee MK, Gonzales V, Jenkins NA, Copeland NG, Price DL, Sisodia SS (1997) Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19, 939-945.
21. Garcia-Alloza M, Robbins EM, Zhang-Nunes SX, Purcell SM, Betensky RA, Raju S, Prada C, Greenberg SM, Bacskai BJ, Frosch MP (2006) Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis 24, 516-524.
22. Cho PY, Joshi G, Johnson JA, Murphy RM (2014) Transthyretin-derived peptides as β-amyloid inhibitors. ACS Chem Neurosci 5, 542-551.
23. Parthsarathy V, McClean PL, Hölscher C, Taylor M, Tinker C, Jones G, Kolosov O, Salvati E, Gregori M, Masserini M, Allsop D (2013) A novel retro-inverso peptide inhibitor reduces amyloid deposition, oxidation and inflammation and stimulates neurogenesis in the APPswe/PS1ΔE9 mouse model of Alzheimer's disease. PLoS One 8, e54769.
24. Wang Q, Liang G, Zhang M, Zhao J, Patel K, Yu X, Zhao C, Ding B, Zhang G, Zhou F, Zheng J (2014) De novo design of self-assembled hexapeptides as β-amyloid (Aβ) peptide inhibitors. ACS Chem Neurosci 5, 972-981.
25. Jucker M, Walker LC (2013) Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 501, 45-51.
26. Kayed R, Lasagna-Reeves CA (2013) Molecular mechanisms of amyloid oligomers toxicity. J Alzheimers Dis 33, S67-S78.
27. Istrate AN, Tsvetkov PO, Mantsyzov AB, Kulikova AA, Kozin SA, Makarov AA, Polshakov VI (2012) NMR solution structure of rat Aβ(1-16): Toward understanding the mechanism of rats' resistance to Alzheimer's disease. Biophys J 102, 136-143.
28. Tsvetkov PO, Popov IA, Nikolaev EN, Archakov AI, Makarov AA, Kozin SA (2008) Isomerization of the Asp7 residue results in zinc-induced oligomerization of Alzheimer's disease amyloid β(1-16) peptide. Chembiochem 9, 1564-1567.
29. Kozin SA, Cheglakov IB, Ovsepyan AA, Telegin GB, Tsvetkov PO, Lisitsa AV, Makarov AA (2013) Peripherally applied synthetic peptide isoAsp7-Aβ(1-42) triggers cerebral β-amyloidosis. Neurotox Res 24, 370-376.